Financial Analysis: Sunshine Biopharma (SBFM) versus Its Competitors

Sunshine Biopharma (NASDAQ:SBFM) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Sunshine Biopharma to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk.

Risk & Volatility

Sunshine Biopharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Sunshine Biopharma’s rivals have a beta of -0.05, meaning that their average stock price is 105% less volatile than the S&P 500.

Earnings and Valuation

This table compares Sunshine Biopharma and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sunshine Biopharma	$36.31 million	-$5.97 million	-0.01
Sunshine Biopharma Competitors	$3.54 billion	$3.17 billion	553.75

Sunshine Biopharma’s rivals have higher revenue and earnings than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.5% of Sunshine Biopharma shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Sunshine Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
Sunshine Biopharma Competitors	-2,393.19%	-220.45%	-16.12%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sunshine Biopharma and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1	1	0	0	1.50
Sunshine Biopharma Competitors	7820	13783	25793	1036	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.87%. Given Sunshine Biopharma’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Sunshine Biopharma has less favorable growth aspects than its rivals.

Summary

Sunshine Biopharma rivals beat Sunshine Biopharma on 9 of the 13 factors compared.

About Sunshine Biopharma

Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.